{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:44:28Z","timestamp":1792421068722,"version":"4.5.0"},"reference-count":20,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,10]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>The incidence of IFIs during VEN-HMA therapy is low, and the used antifungal prophylaxis approach did not influence the risk of IFIs. The risk of IFIs is higher in nonresponders and those who were treated in the r\/r AML setting.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000930","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T16:32:34Z","timestamp":1575909154000},"page":"4043-4049","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":86,"title":["Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents"],"prefix":"10.1182","volume":"3","author":[{"given":"Ibrahim","family":"Aldoss","sequence":"first","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeet","family":"Dadwal","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Information Sciences, City of Hope Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Tegtmeier","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1109-6955","authenticated-orcid":false,"given":"Matthew","family":"Mei","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukaib","family":"Arslan","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monzr M.","family":"Al Malki","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Salhotra","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-7292","authenticated-orcid":false,"given":"Haris","family":"Ali","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Aribi","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karamjeet","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Khaled","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Snyder","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0680","authenticated-orcid":false,"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Stein","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Pullarkat","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"issue":"1","key":"2019120911322892600_B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2019120911322892600_B2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","article-title":"A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy","volume":"97","author":"L\u00fcbbert","year":"2012","journal-title":"Haematologica"},{"issue":"21","key":"2019120911322892600_B3","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019120911322892600_B4","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"2019120911322892600_B5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"issue":"10","key":"2019120911322892600_B6","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.25567","article-title":"Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"94","author":"Aldoss","year":"2019","journal-title":"Am J Hematol"},{"issue":"2","key":"2019120911322892600_B7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2141.2000.02014.x","article-title":"Towards a targeted, risk-based, antifungal strategy in neutropenic patients","volume":"110","author":"Prentice","year":"2000","journal-title":"Br J Haematol"},{"issue":"23","key":"2019120911322892600_B8","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1200\/JCO.2008.21.0856","article-title":"Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve","volume":"27","author":"Portugal","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019120911322892600_B9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/0003-4819-100-3-345","article-title":"Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia","volume":"100","author":"Gerson","year":"1984","journal-title":"Ann Intern Med"},{"issue":"2","key":"2019120911322892600_B10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther"},{"issue":"12","key":"2019120911322892600_B11","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2019120911322892600_B12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/myc.12500","article-title":"Invasive fungal infections in AML\/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?","volume":"59","author":"Pomares","year":"2016","journal-title":"Mycoses"},{"issue":"34","key":"2019120911322892600_B13","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1200\/JCO.2007.12.3851","article-title":"Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis","volume":"25","author":"Robenshtok","year":"2007","journal-title":"J Clin Oncol"},{"issue":"30","key":"2019120911322892600_B14","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019120911322892600_B15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"2019120911322892600_B16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jinf.2018.03.015","article-title":"Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: a randomized study","volume":"77","author":"Epstein","year":"2018","journal-title":"J Infect"},{"issue":"5","key":"2019120911322892600_B17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","article-title":"Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study","volume":"21","author":"Wexler","year":"2004","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"2019120911322892600_B18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ajh.25369","article-title":"Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: update on clinical trial data and practical considerations for use","volume":"94","author":"Mei","year":"2019","journal-title":"Am J Hematol"},{"issue":"8","key":"2019120911322892600_B19","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1097\/MPH.0b013e3182331bc7","article-title":"Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study","volume":"33","author":"Mandhaniya","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"2019120911322892600_B20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2018-99-117179","article-title":"Venetoclax in combination with hypomethylating agents induces rapid, deep, and durable responses in patients with AML ineligible for intensive therapy","volume":"132(suppl 1)","author":"Pollyea","year":"2018","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/23\/4043\/1546913\/advancesadv2019000930.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/23\/4043\/1546913\/advancesadv2019000930.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T20:09:05Z","timestamp":1695499745000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/23\/4043\/429582\/Invasive-fungal-infections-in-acute-myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":20,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000930","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,9]]}}}